Full-Time

Scientific Technical Lead

Early Stage PDST CMC

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$109.5k - $208.5k/yr

+ Long-term incentive program

North Chicago, IL, USA

Hybrid

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
LLM
Scikit-learn
Dataiku
MLOps
Python
Data Science
TensorFlow
R
PyTorch
Apache Spark
Machine Learning
Data Engineering
RAG
Tableau
Pandas
Business Analytics
NumPy
Data Analysis

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A bachelor's degree in computer science or a related discipline with 7 years of experience, a master's degree with 6 years of experience, or a PhD with 2 years of experience in information technology or application program development.
  • Hands-on experience building and deploying data science or machine learning solutions in a scientific or engineering-intensive environment.
  • Expert-level Python proficiency and deep familiarity with NumPy, pandas, scikit-learn, PyTorch or TensorFlow, and modern data engineering including cloud, big data, and pipeline orchestration.
  • A strong foundation in business analytics and mastery of R, Dataiku, AWS SageMaker, Spark, and Tableau.
  • Experience with design of experiments methodologies, Bayesian methods, or active learning in scientific applications.
  • Familiarity with knowledge graphs, retrieval-augmented systems, or orchestrated artificial intelligence and large language model systems applied to scientific or technical domains.
  • Experience applying data science in a GxP-regulated environment, with working knowledge of FDA and EMA expectations for process validation, continued process verification, and control strategy.
  • Familiarity with MLOps principles, model lifecycle management, or deployment of analytical tools in regulated or enterprise environments.
  • Ownership of problem spaces, solutions, and outcomes through completion.
  • Ability to evaluate available approaches and select fit-for-purpose tools as a solution architect.
  • Ability to build models that are explainable, defensible, and improvable.
  • Ability to earn the confidence of scientists, engineers, and quality professionals through accurate, clear, and useful work.
  • Ability to work effectively on high-impact analytical problems in ambiguous situations.
Responsibilities
  • Develop, validate, and deploy predictive models supporting early-stage biologics process development decisions, including upstream bioprocess performance, downstream purification behavior, and critical quality attribute outcomes.
  • Design and apply hybrid modeling approaches that combine first-principles process understanding with data-driven techniques while maintaining scientific interpretability.
  • Build and evolve analytical frameworks supporting digital twin concepts and in-silico process optimization.
  • Partner with process scientists, analytical scientists, and engineers to define data strategies, including data collection, structure, and connections across experimental campaigns.
  • Identify and address data quality, integration, and accessibility challenges, and help implement improved data infrastructure within the pod.
  • Ensure models, analyses, and data assets follow GxP principles and regulatory expectations with appropriate documentation and traceability.
  • Serve as a solution architect for analytical and AI-driven workflows, selecting classical statistical methods, supervised or unsupervised machine learning, retrieval-augmented generation, orchestrated AI pipelines, or hybrid mechanisms based on scientific need, data availability, and interpretability.
  • Identify opportunities to automate, accelerate, or augment scientific workflows and scope, build, and validate those solutions.
  • Evaluate emerging artificial intelligence and machine learning approaches for applicability to biologics development.
  • Collaborate with process development scientists to design statistically rigorous, resource-efficient, and informative experiments using design of experiments, Bayesian optimization, and active learning strategies.
  • Support process characterization studies through statistical analysis, model-based risk assessment, and data-driven identification of critical process parameters and their relationships to critical quality attributes.
  • Develop analytical frameworks that translate process understanding into transferable, defensible process knowledge for technology transfer readiness.
  • Translate complex quantitative analyses into clear, actionable insights for scientists, engineers, and senior leaders.
  • Participate in cross-functional discussions and contribute data-driven perspectives to program decisions, risk assessments, and development strategies.
  • Document, present, and defend analytical work for internal technical reviews and regulatory submissions.
Desired Qualifications
  • An advanced degree such as a Master of Science or PhD in Data Science, Biostatistics, Chemical Engineering, Biochemical Engineering, Computational Biology, or a closely related quantitative discipline.
  • Five or more years of hands-on experience building and deploying data science or machine learning solutions in a scientific or engineering-intensive environment.
  • Experience working with data from laboratory and manufacturing systems such as LIMS, MES, DeltaV or historian systems, and electronic batch record platforms, and building scalable data pipelines for process analytics.
  • Direct experience in biologics or bioprocess development, including cell culture, fermentation, chromatography, filtration, or formulation, in an industrial or academic research setting.
  • Familiarity with CMC development concepts, including process characterization, scale-up, technology transfer, or regulatory filing support for BLA or IND submissions.
  • Familiarity with biopharmaceutical data types including bioreactor process data, chromatography profiles, analytical assay results, and spectroscopic measurements.
  • Familiarity with technology transfer workflows, process characterization study design, or commercial process validation in a biologics or pharmaceutical context.
  • A track record of scientific communication through publications, regulatory submissions, technical reports, or equivalent work demonstrating clear and credible communication of complex analytical work.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.99 billion, up 10.2%, with EPS of $3.65.
  • AbbVie raised 2026 guidance to $13.87-$14.07 after broad strength across immunology and neuroscience.
  • Rinvoq and Skyrizi both grew above 23% operationally, showing durable post-Humira momentum.

What critics are saying

  • Humira sales fell 36.1% in Q2 2026; biosimilars keep compressing cash flows.
  • Imbruvica dropped 29.4% in Q2 2026, exposing oncology weakness and IRA pricing damage.
  • Apogee dilutes adjusted EPS through 2027; if Skyrizi stalls, AbbVie loses its bridge.

What makes AbbVie unique

  • Skyrizi and Rinvoq delivered $8.0 billion in Q2 2026, replacing Humira.
  • AbbVie completed Apogee on September 3, 2026, adding long-acting immunology assets.
  • Etentamig posted 74% response in Phase 3 multiple myeloma, broadening oncology optionality.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Sep 10th, 2026
AbbVie shifts focus from declining Humira to $8B Skyrizi and Rinvoq growth engines

AbbVie has dramatically shifted its focus away from Humira, its once-flagship drug now facing biosimilar competition. On the company's July 2026 earnings call, Humira received just one sentence, noting global sales of $706 million, down 36.1% operationally but in line with expectations. This marks a stark change from previous quarters when management detailed the reasons behind Humira's decline, including biosimilar competition and molecule compression in the US market. AbbVie now emphasises growth drivers instead. Skyrizi generated $5.5 billion in Q2 2026, whilst Rinvoq exceeded $2.5 billion, both growing above 20% operationally. The company also acquired Apogee Therapeutics in September 2026. Despite the reduced attention, Humira still contributes approximately 4% of AbbVie's quarterly revenue of nearly $17 billion, though management no longer publicly projects its ultimate decline trajectory.

Yahoo Finance
Sep 9th, 2026
Billionaire hedge fund manager doubles down on AbbVie and Costco dividend stocks

Israel Englander's Millennium Management more than doubled its stakes in AbbVie and Costco during the second quarter. AbbVie's revenue grew 10.2% year-over-year to $17 billion in Q2, driven by immunology drugs Skyrizi and Rinvoq. The company recently acquired Apogee Therapeutics for $10.9 billion in cash and is developing ABBV-295, a monthly weight-loss treatment. AbbVie is a Dividend King with over 50 consecutive years of payout increases. Costco's Q3 fiscal 2026 revenue rose 11.6% to $70.5 billion, with comparable sales up 9.8%. The company has raised dividends for 22 consecutive years. However, Costco shares are down 4% over the past year whilst trading at 40.8 times forward earnings, above the consumer staples average of 21.6 times. Both companies maintain strong fundamentals despite different market challenges.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

INSURASALES
Sep 5th, 2026
Manufacturers Life Insurance buys $655M stake in AbbVie as institutions boost pharma holdings

The Manufacturers Life Insurance Company acquired a $655.27 million stake in AbbVie Inc., according to its latest SEC Form 13F filing. Other institutional investors also increased their positions significantly during the same period. Norges Bank acquired a new $5.87 billion position, whilst Wellington Management Group boosted its holdings by 457.4%. AbbVie reported quarterly earnings per share of $3.65, exceeding forecasts, with revenue growth of 10.2% year over year. The company generated $16.99 billion in revenue last quarter, surpassing expectations. Equity analysts maintain a bullish outlook. Barclays, Wolfe Research, and BMO Capital Markets each set price targets of $300, with ratings of "overweight" or "outperform". The consensus rating is "Moderate Buy". Institutional investors currently hold 70.23% of AbbVie's shares, reflecting confidence in the biopharmaceutical company's strategy and performance.

PharmTech
Sep 4th, 2026
AAPS PharmSci 360: CMC strategies, part 1.

AAPS PharmSci 360: CMC strategies, part 1. In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy. PharmTech spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy. Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions. Singh cautioned, however, that companies must build "risk justification muscle" rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators. Rumondor addressed the pressure to compress development timelines. He argued the real question isn't whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor. About the speakers. Alfred Rumondor, PhD, is Director, Development Sciences Licensing and Acquisitions, at AbbVie. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.